|
Monday, December 14, 2009
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
Lankenau Chemical Genomics Center
Services for Accelerating Exploration of Chemical & Biological Space
About
|
LCGC has developed a new method and system of high-throughput, remarkably efficient, automated sample retrieval ideally suited for managing large compound libraries for high throughput screening. There are significant cost advantages for the device; their technology is 3-fold less expensive then presently adapted automation and offers far more flexible installations. LCGC was just awarded a Phase I SBIR to refine the technology. They are unsure whether they want to go into the hardware business; rather, they see potentially transformative research services applications.
Complementing the hardware, LCGC has an interesting, rather unique drug-like compound library of 140,000 members that they have formatted with the orthogonal compression method that allows drug screening with 80% fewer resources than present practice. LCGC intends to provide high-end, turnkey research materials management services that are enabling to start-ups and academic labs (NIH and NCI, well-funded labs) engaged in ongoing high throughput screening. Their approaches also have compelling applications for the emerging biorepository space, which is presently stymied by cumbersome storage and retrieval techniques.
3 Major Issues
|
-
Should LCGC look for a licensee for the technology, rather than contemplate models of directly marketing a sophisticated device requiring coordinated engineering support?
-
The issues related to providing sample access for genetic screening are remarkably similar to the early days of high throughput screening, when materials management issues were rate limiting to research. What are the most important business models whereby the LCGC infrastructure might have the greatest impact in the biorepository field, particularly for pharma?
-
LCGC desires to serve as an arms-length, enabling infrastructure to provide blinded access for leading academic labs to diversity and focused representative sets of pharma compound libraries that are compressed for accelerated screening. What IP issues present the greatest issues to this new model?
-
A fourth question will be thrown out to the audience for commentary: In today's uncertain environment, what types of investors might be attracted to LCGC business models, and how might they focus to attract?
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 -Tim Pelura PhD, President & CEO of Immunome will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
Contact Info:
Mel Reichman, Ph.D.
Director LIMR Chemical Genomics Center (LCGC)
100 Lancaster Ave
Wynnewood, PA 19096
TEL: (610) 645-8230
FAX: (610) 645-2205
EMAIL: reichmanm@mlhs.org
WEB: www.limr.org
|
|
|
Slides
Audio
Video
Webcast
